Novel CAR T-cell therapies for hematological malignancies: exploring new targets

A novel subcutaneous CAR-T therapy for the treatment of hematological malignanciesПодробнее

New indications for CAR-T therapies in hematological malignanciesПодробнее

Novel Therapies in Aggressive Lymphoma & CAR T-cell TherapyПодробнее

Anito-Cel, a novel anti-BCMA CAR T-cell, for Relapsed/Refractory Myeloma | Ciara Freeman | #ASH24Подробнее

CAR T-cells in hematological malignanciesПодробнее

Tackling resistance to CAR-T therapy across hematological malignanciesПодробнее

Novel strategies to optimize CAR T-cell therapyПодробнее

Development and evaluation of a novel CAR-T cell therapy against CALR mutant neoplasmsПодробнее

How CAR T-Cell Therapy Has Evolved in Hematologic MalignanciesПодробнее

CB011: a novel genome-engineered BCMA-specific CAR-T cell therapyПодробнее

The emergence of novel antibodies, CAR-T and CAR-NK therapies in AMLПодробнее

Identifying novel antigens for TCR T-cell therapyПодробнее

CAR T-Cell Therapy for Hematological Malignancies Other Than CD19Подробнее

Anti-CD22 CAR T-cell therapy for ALL: trial update, utility for salvage and CD19 statusПодробнее

Immune Effector Cell Therapy in Hematologic Malignancies: Lessons LearnedПодробнее

BMS-986393, a novel anti-GPRC5D CAR-T cell therapy, in multiple myelomaПодробнее

Webinar: Engineering strategies for improving adoptive T cell therapy against cancerПодробнее

Episode 34 – Travis Young: Finding a cure for cancer with novel immunotherapiesПодробнее

Exciting developments in CAR-T therapies in and beyond hematological malignanciesПодробнее